Food allergy, anaphylaxis, dermatology, and drug allergyPediatric patients with eosinophilic esophagitis: An 8-year follow-up
Section snippets
Patients
Pediatric patients evaluated in our center with gastrointestinal symptoms who had esophagogastroduodenoscopy with the diagnosis of EE were included. After obtaining informed consent, patients' data were entered in a database approved by the Institutional Review Board of Cincinnati Children's Hospital Medical Center.
Demographics and symptoms
Data were extracted from the medical history obtained at the patient's first visit to our center. The age of onset and the age at diagnosis were defined as the age at which the
Patients
Eighty-nine patients who had at least 1 esophagogastroduodenoscopy with 1 histopathologic diagnosis of EE were included in the study. All patients were evaluated in our center between March 31, 1997, and November 30, 2004. The initial histopathologic diagnosis was made in our center for 57 patients. Thirty-two patients whose initial histopathology was interpreted at other institutions and was not available for interpretation at our center were included in our analysis because at least 1
Discussion
Herein we report several new findings concerning pediatric EE. The first is the prolonged lag of time, as long as 3 years, between onset of symptoms and the first diagnostic endoscopy. The symptoms had remained the same at the time of onset and at the time of the first endoscopy, which suggests that the persistence of symptoms, rather than their severity, was the reason for the endoscopic evaluation. Another intriguing finding is the age distribution of the affected children. The highest
References (22)
- et al.
Surgical manifestations of eosinophilic gastroenteritis in the pediatric patient
J Pediatr Surg
(1977) - et al.
Benefit of ketotifen in patients with eosinophilic gastroenteritis
Am J Med
(1991) - et al.
Milk-sensitive and eosinophilic gastroenteropathy: similar clinical features with contrasting mechanisms and clinical course
J Allergy Clin Immunol
(1984) - et al.
Eosinophilic esophagitis attributed to gastroesophageal reflux: improvement with an amino acid-based formula
Gastroenterology
(1995) - et al.
The spectrum of pediatric eosinophilic esophagitis beyond infancy: a clinical series of 30 children
Am J Gastroenterol
(2000) - et al.
Eosinophilic esophagitis: a 10-year experience in 381 children
Clin Gastroenterol Hepatol
(2005) - et al.
Treatment of eosinophilic esophagitis with specific food elimination diet directed by a combination of skin prick and patch tests
Ann Allergy Asthma Immunol
(2005) - et al.
Elemental diet is an effective treatment for eosinophilic esophagitis in children and adolescents
Am J Gastroenterol
(2003) - et al.
Eosinophilic esophagitis in children: immunopathological analysis and response to fluticasone propionate
Gastroenterology
(2002) - et al.
Successful medical treatment of two patients with eosinophilic oesophagitis
J Pediatr Surg
(2002)
Cited by (294)
Eosinophilic Esophagitis: What the Otolaryngologist Needs to Know
2024, Otolaryngologic Clinics of North AmericaTranscriptomic profiling of the acute mucosal response to local food injections in adults with eosinophilic esophagitis
2024, Journal of Allergy and Clinical ImmunologyPathophysiology and Clinical Impact of Esophageal Remodeling and Fibrosis in Eosinophilic Esophagitis
2024, Immunology and Allergy Clinics of North AmericaClinical Evaluation of the Child with Eosinophilic Esophagitis
2024, Immunology and Allergy Clinics of North AmericaDevelopment of a Practical Guide to Implement and Monitor Diet Therapy for Eosinophilic Esophagitis
2023, Clinical Gastroenterology and HepatologyFood Allergy Characteristics Associated With Coexisting Eosinophilic Esophagitis in FARE Registry Participants
2023, Journal of Allergy and Clinical Immunology: In Practice
Supported by a 2005 American Academy of Allergy, Asthma & Immunology/Sanofi Aventis Women Physicians in Allergy Project Grant Award (A.H.A.) and a 2004 American Academy of Allergy, Asthma & Immunology Clinical Fellowship Award (J.Z.B.).
Disclosure of potential conflict of interest: A. H. Assa'ad has consulting arrangements with and has received grant support from GlaxoSmithKline. M. H. Collins has consulting arrangements with GlaxoSmithKline and Ception Therapeutics. R. J. Noel has consulting arrangements with Ception Therapeutics. M. E. Rothenberg has consulting arrangements with GlaxoSmithKline, Ception Therapeutics, Cambridge Antibody Technology, Tanox, and MedaCorp; owns stock in Ception Therapeutics; has received grant support from Cambridge Antibody Technology; and is on the speakers' bureau for Merck. The rest of the authors have declared that they have no conflict of interest.